Vaxil: Management and Operational Update
Not for distribution by US newswire or in United States
Read the original:
Vaxil: Management and Operational Update
Author Archives: admin
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
FOSTER CITY, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the fiscal year ended December 31, 2024, and highlighted clinical updates and business progress.
See the rest here:
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update
-- Recorded Revenues of $35.2 Million for Q3 Fiscal 2025 ---- Signed Multiple Development Agreements with New and Existing Customers --
Continue reading here:
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update
Praxis Precision Medicines to Participate in Upcoming April Conferences
BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences this April:
Read this article:
Praxis Precision Medicines to Participate in Upcoming April Conferences
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update
MONTREAL, April 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results and provide a business update for its first quarter 2025 ended February 28 on Wednesday, April 9, 2025, at 8:30 a.m. ET.
Go here to see the original:
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update
Anne Whitaker Appointed as Non-Executive Director
MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251.
Read more:
Anne Whitaker Appointed as Non-Executive Director
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN)…
Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points
Read more from the original source:
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN)...
Zelluna ASA [ZLNA]: Notice of Annual General Meeting on April 29, 2025
Oslo, April 04, 2025, the Board of Directors hereby calls for the Annual General Meeting of Zelluna ASA at 14:00 CET on April 29, 2025.
More:
Zelluna ASA [ZLNA]: Notice of Annual General Meeting on April 29, 2025
Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the status of its products in relation to the U.S. Government’s announcement on tariffs for imported products. Mesoblast believes that its allogeneic cellular products, including Ryoncil® and Revascor®, will not be subject to the tariffs.
See the original post:
Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs
Dogecoin Cash, Inc. Subsidiary PrestoDoctor Launches April Promotion Offering 42.0% Off Medical Cannabis Evaluations
MESQUITE, NV, April 04, 2025 (GLOBE NEWSWIRE) -- Mesquite, NV — Dogecoin Cash, Inc. (OTCIQ: CBDS), is pleased to announce that its subsidiary, PrestoDoctor (www.prestodoctor.com), is rolling out a limited-time April promotion offering 42.0% off medical cannabis card evaluations and renewals throughout the month of April, our largest ever discount.
Read the original post:
Dogecoin Cash, Inc. Subsidiary PrestoDoctor Launches April Promotion Offering 42.0% Off Medical Cannabis Evaluations